0001415889-24-002613.txt : 20240205
0001415889-24-002613.hdr.sgml : 20240205
20240205173910
ACCESSION NUMBER: 0001415889-24-002613
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eydelman Mikhail
CENTRAL INDEX KEY: 0001918033
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 24597070
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, SUITE 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
form4-02052024_100258.xml
X0508
4
2024-02-01
0001649094
Vaxcyte, Inc.
PCVX
0001918033
Eydelman Mikhail
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, SUITE 300
SAN CARLOS
CA
94070
false
true
false
false
SVP, GEN COUNSEL & CORP SEC
1
Common Stock
2024-02-01
4
M
0
1667
21.41
A
22377
D
Common Stock
2024-02-01
4
S
0
212
72.215
D
22165
D
Common Stock
2024-02-01
4
S
0
638
73.165
D
21527
D
Common Stock
2024-02-01
4
S
0
343
74.11
D
21184
D
Common Stock
2024-02-01
4
S
0
474
75.391
D
20710
D
Stock Option (Right to Buy)
21.41
2024-02-01
4
M
0
1667
0
D
2032-05-08
Common Stock
1667
191666
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $72.695 to $73.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $73.70 to $74.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $75.01 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Mikhail Eydelman, by /s/ Andrew Guggenhime, Attorney-in-Fact
2024-02-05